Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.

ABSTRACT:

Background

The opioid antagonist naltrexone has shown promise to reduce weight gain during active treatment, but longer-term studies have not been conducted. The goal was to examine effects of naltrexone on weight gain over long-term follow-up in men and women who quit smoking.

Methods

Weight was examined at baseline and 6- and 12-month follow-up in the two largest randomized, double-blind, placebo-controlled trials of naltrexone in nicotine dependence. For 6-12 weeks after the quit date, participants were randomly assigned to receive naltrexone or placebo. Behavioral counseling and open-label nicotine patch were also included for the first 4-6 weeks. Of the 700 participants in the combined intent-to-treat sample, there were 159 (77 women) biochemically verified abstinent sm

SUBMITTER: King AC 

PROVIDER: S-EPMC3629005 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature